1. ALLA AKTIER
  2. NYHETER
  3. IDL DIAGNOSTICS

IDL Diagnostics

Nyheter IDL Diagnostics Nyheter alla bolag
Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

AroCell publishes the Annual Report for 2024

MARKN.

AroCell hereby announces that the annual report for 2024 has now been published and is available on the company’s website: www.arocell.com.

The annual report is available on the following link: www.arocell.com/investors/financial-reports/

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments

Årsredovisning 2024

Datum 2025-04-11, kl 08:00
Källa MFN
Bifogade filer
Årsredovisning 2024